Esperion Therapeutics Ownership | Who Owns Esperion Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Esperion Therapeutics Ownership Summary

Esperion Therapeutics is owned by 49.10% institutional investors, 0.61% insiders, and 50.29% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 8.92% of ESPR shares. BB Biotech AG Ord is the top mutual fund, with 5.05% of its assets in Esperion Therapeutics shares.

ESPR Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Esperion Therapeutics	49.10%	0.61%	50.29%
Sector	Healthcare Stocks	232.86%	10.65%	-143.51%
Industry	Specialty & Generic Drug Manufacturers Stocks	20.25%	11.78%	67.97%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock funding, inc. /de	17.68M	8.92%	$65.42M
Blackrock	13.98M	8.26%	$31.04M
Wasatch advisors lp	15.77M	7.59%	$43.21M
Vanguard group	14.95M	7.54%	$55.30M
Two seas capital lp	11.90M	6.01%	$44.04M
Penderfund capital management	6.68M	3.39%	$17.69M
Geode capital management	5.74M	2.90%	$21.23M
State street	4.48M	2.28%	$11.87M
Meditor group	3.79M	2.24%	$8.42M
Aigh capital management	4.00M	2.02%	$14.80M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Meditor group	3.79M	15.57%	$8.42M
Aigh capital management	4.00M	3.58%	$14.80M
Penderfund capital management	6.68M	2.98%	$17.69M
Two seas capital lp	11.90M	0.91%	$44.04M
Caitong asset management	30.46K	0.31%	$112.71K
Summit wealth group	340.61K	0.29%	$1.26M
Wasatch advisors lp	15.77M	0.29%	$43.21M
Integral health asset management	1.50M	0.27%	$3.98M
Diametric capital, lp	236.15K	0.23%	$625.78K
Logos global management lp	750.00K	0.18%	$1.99M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	13.98M	0.00%	11.14M
Wasatch advisors lp	15.77M	0.29%	6.32M
Vanguard group	14.95M	0.00%	2.85M
Blackrock funding, inc. /de	17.68M	0.00%	2.85M
Two seas capital lp	11.90M	0.91%	2.15M

Top Sellers

Holder	Shares	% Assets	Change
Orbimed advisors	-	-	-13.71M
Bellevue group	-	-	-9.69M
Great point partners	-	-	-5.79M
Bank of america corp /de/	1.16M	0.00%	-3.38M
Indaba capital management	-	-	-3.00M

New Positions

Holder	Shares	% Assets	Change	Value
Integral health asset management	1.50M	0.27%	1.50M	$3.98M
Logos global management lp	750.00K	0.18%	750.00K	$1.99M
Walleye capital	319.19K	0.00%	319.19K	$845.86K
Voleon capital management lp	207.88K	0.01%	207.88K	$550.88K
Eleva capital sas	183.05K	0.15%	183.05K	$501.55K

Sold Out

Holder	Change
True wealth design	-1.00
Assetmark	-8.00
Td waterhouse canada	-59.00
Farther finance advisors	-90.00
Rothschild investment	-100.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	137	-31.50%	97,287,936	-9.92%	49	1.63%	75	-29.25%	21	-43.24%
Sep 30, 2025	119	-26.54%	54,298,682	-41.97%	27	1.22%	59	-13.24%	23	-41.03%
Jun 30, 2025	168	-11.58%	98,172,969	-13.34%	49	1.49%	67	-17.28%	44	-21.43%
Mar 31, 2025	190	-7.77%	113,479,021	-9.95%	57	1.38%	82	-8.89%	56	21.74%
Dec 31, 2024	86	-56.78%	36,541,743	-71.74%	18	0.43%	38	-51.28%	15	-65.91%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
BB Biotech AG Ord	9.94M	5.05%	-
Pender Corporate Bond F	6.36M	3.18%	359.98K
Vanguard US Total Market Shares ETF	6.18M	3.12%	-
Vanguard Total Stock Mkt Idx Inv	7.53M	2.93%	-
iShares Russell 2000 ETF	5.85M	2.28%	-47.75K
Wasatch Small Cap Growth Investor	4.35M	2.21%	-43.99K
Wasatch Ultra Growth	4.42M	1.85%	-16.74K
Pender Corporate Bond A	4.06M	1.58%	-
Wasatch Micro Cap	2.82M	1.18%	2.82M
Nuveen Quant Small Cap Equity R6	3.02M	1.17%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 17, 2026	Looker Benjamin	Chief Legal Officer	Sell	$15.43K
Mar 17, 2026	Koenig Sheldon L.	President and CEO	Sell	$69.55K
Mar 17, 2026	Halladay Benjamin	Chief Financial Officer	Sell	$17.38K
Jan 20, 2026	Looker Benjamin	General Counsel	Sell	$4.87K
Dec 17, 2025	Koenig Sheldon L.	President and CEO	Sell	$177.20K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	4
2025 Q4	-	3
2025 Q3	-	5
2025 Q2	-	5
2025 Q1	-	7

ESPR Ownership FAQ

Who Owns Esperion Therapeutics?

Esperion Therapeutics shareholders are primarily institutional investors at 49.10%, followed by 0.61% insiders and 50.29% retail investors. The average institutional ownership in Esperion Therapeutics's industry, Specialty & Generic Drug Manufacturers Stocks, is 20.25%, which Esperion Therapeutics exceeds.

Who owns the most shares of Esperion Therapeutics?

Esperion Therapeutics’s largest shareholders are Blackrock funding, inc. /de (17.68M shares, 8.92%), Blackrock (13.98M shares, 8.26%), and Wasatch advisors lp (15.77M shares, 7.59%). Together, they hold 24.77% of Esperion Therapeutics’s total shares outstanding.

Does Blackrock own Esperion Therapeutics?

Yes, BlackRock owns 8.26% of Esperion Therapeutics, totaling 13.98M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 31.04M$. In the last quarter, BlackRock increased its holdings by 11.14M shares, a 392.59% change.

Who is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested?

Meditor group is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested, with 15.57% of its assets in 3.79M Esperion Therapeutics shares, valued at 8.42M$.

Who is the top mutual fund holder of Esperion Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Esperion Therapeutics shares, with 5.05% of its total shares outstanding invested in 9.94M Esperion Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools